Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases. To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (α-thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres, were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n = 784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [3]
In the citing paper
“Indeed, the K27M mutation has been observed to occur in genes encoding all forms of histone H3 (H3.1, H3.2, and H3.3) in human glioma (1,10,24).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [1]
In the citing paper
“ALT is associated with mutations in the chromatin remodeller α-thalassaemia/mental retardation syndrome X-linked (AT R X ) both in vitro and in several human cancers, including glioblastomas162–165.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [163]
In the citing paper
“The H3.3G34R/V mutated tumours are found almost exclusively in the cerebral hemispheres 101,102 , whereas H3.1K27M tumours are restricted to an area of the brainstem called the pons and H3.3K27M tumours can also be found along the midline of the brain 106 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [106]
In the citing paper
“A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors, and results in a lysine-to-methionine substitution (H3K27M)2,3.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [2]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cited by
Items 101–200 of 1,001
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Guerreiro Stucklin, A. S., Ryall, S., Fukuoka, K., Zapotocky, M., Lassaletta, A., Li, C., Bridge, T., Kim, B., Arnoldo, A., Kowalski, P. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12187-5 · Cited by 367
Self-citationMorgan, M. A. J., & Shilatifard, A. (2020) · Nature Genetics · doi:10.1038/s41588-020-00736-4 · Cited by 355
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
“101 These fi ndings emphasize that ATRX mutations are key molecular markers for glioma classi fi cation and potential therapeutic intervention.”
BET Bromodomain Inhibition of MYC -Amplified Medulloblastoma
Bandopadhayay, P., Bergthold, G., Nguyen, B., Schubert, S., Gholamin, S., Tang, Y., Bolin, S., Schumacher, S. E., Zeid, R., Masoud, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2281 · Cited by 352
“It is increasingly recognized that genomic alterations may result in global epigenetic dysregulation in pediatric brain tumors(42-44).”
Pediatric high-grade glioma: biologically and clinically in need of new thinking
Jones, C., Karajannis, M. A., Jones, D. T. W., Kieran, M. W., Monje, M., Baker, S. J., Becher, O. J., Cho, Y.-J., Gupta, N., Hawkins, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now101 · Cited by 360
Self-citationPediatric low-grade glioma in the era of molecular diagnostics
Ryall, S., Tabori, U., & Hawkins, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00902-z · Cited by 351
“K27M is exclusively observed in tumors arising in the midline, including the pons, diencephalon/thalamus and spinal cord [66, 109, 134, 193, 207, 226, 227].”
Self-citationHarutyunyan, A. S., Krug, B., Chen, H., Papillon-Cavanagh, S., Zeinieh, M., De Jay, N., Deshmukh, S., Chen, C. C. L., Belle, J., Mikael, L. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09140-x · Cited by 360
Self-citationPrognostic and Predictive Biomarkers in Gliomas
Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910373 · Cited by 340
India Project Team of the International Cancer Genome Consortium, Maitra, A., Biswas, N. K., Amin, K., Kowtal, P., Kumar, S., Das, S., Sarin, R., Majumder, P. P., Bagchi, I., et al. (2013) · Nature Communications · doi:10.1038/ncomms3873 · Cited by 355
Variants of core histones and their roles in cell fate decisions, development and cancer
Buschbeck, M., & Hake, S. B. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.166 · Cited by 335
ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression
Wen, H., Li, Y., Xi, Y., Jiang, S., Stratton, S., Peng, D., Tanaka, K., Ren, Y., Xia, Z., Wu, J., et al. (2014) · Nature · doi:10.1038/nature13045 · Cited by 343
Buczkowicz, P., Bartels, U., Bouffet, E., Becher, O., & Hawkins, C. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1319-6 · Cited by 350
“The mutation, resulting in replacement of a lysine with methionine (K27M), is present in approximately 70 % of DIPgs versus 21 % of, largely midline thalamic, supratentorial gBMs [10, 22].”
BackgroundRecurrent somatic mutations in POLR2A define a distinct subset of meningiomas
Clark, V. E., Harmancı, A. S., Bai, H., Youngblood, M. W., Lee, T. I., Baranoski, J. F., Ercan-Sencicek, A. G., Abraham, B. J., Weintraub, A. S., Hnisz, D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3651 · Cited by 354
Korshunov, A., Ryzhova, M., Hovestadt, V., Bender, S., Sturm, D., Capper, D., Meyer, J., Schrimpf, D., Kool, M., Northcott, P. A., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1405-4 · Cited by 350
“1 genes (HIST1H3B and HIST1H3C) are frequent in pediatric GBM (approximately 40 % of tumors) but rare in adults [1, 7, 14, 22, 27, 41, 46, 48, 52, 53].”
BackgroundSelf-citationChromatin repressive complexes in stem cells, development, and cancer
Laugesen, A., & Helin, K. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.05.006 · Cited by 352
Rondinelli, B., Gogola, E., Yücel, H., Duarte, A. A., van de Ven, M., van der Sluijs, R., Konstantinopoulos, P. A., Jonkers, J., Ceccaldi, R., Rottenberg, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3626 · Cited by 332
Wiestler, B., Capper, D., Holland-Letz, T., Korshunov, A., von Deimling, A., Pfister, S. M., Platten, M., Weller, M., & Wick, W. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1156-z · Cited by 346
“However, given that almost all tumors in this NOA-04 biomarker cohort which had ATRX loss were IDH mutated (Table 2), and H3F3A and IDH mutations are mutually exclusive [20, 22], we did not test for H3F3A mutations.”
BackgroundMethodInfluentialSelf-citationPediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
Sturm, D., Pfister, S. M., & Jones, D. T. W. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0242 · Cited by 339
“tumors.(46,49) Other molecular features include a high percentage of TP53 mutations (.”
BackgroundInfluentialSelf-citationPrime, Repair, Restore: The Active Role of Chromatin in the DNA Damage Response
Soria, G., Polo, S. E., & Almouzni, G. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.002 · Cited by 342
Promise of personalized omics to precision medicine
Chen, R., & Snyder, M. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1198 · Cited by 323
Biomolecular Condensates and Cancer
Boija, A., Klein, I. A., & Young, R. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.003 · Cited by 327
“For example, the oncogenic histone mutation H3K27M frequently occurs in childhood brain-stem gliomas and changes the chromatin landscape from poised to active at bivalent promoters, resulting in dysregulated gene expression (Larson et al., 2019; Schwartzentruber et al., 2012; Wu et al., 2014).”
BackgroundKundu, S., Ji, F., Sunwoo, H., Jain, G., Lee, J. T., Sadreyev, R. I., Dekker, J., & Kingston, R. E. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.01.009 · Cited by 333
“…(Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Lewis et al., 2013; M€uller et al., 2002; Pengelly et al., 432 Molecular Cell 65, 432–446, February 2, 2017 ª 2017 Elsevier Inc 2013; Schwartzentruber et al., 2012; Simon and Kingston, 2013; Voigt and Reinberg, 2013; Wu et al., 2012).”
BackgroundHistone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D., Taylor, K. R., Vinci, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0426 · Cited by 318
“B, gene set enrichment analysis (GSEA) for differential gene expression signatures identifi ed by Schwartzentruber and colleagues (2) versus those from Paugh and colleagues (3).”
InfluentialSpatiotemporal Evolution of the Primary Glioblastoma Genome
Kim, J., Lee, I.-H., Cho, H. J., Park, C.-K., Jung, Y.-S., Kim, Y., Nam, S. H., Kim, B. S., Johnson, M. D., Kong, D.-S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.013 · Cited by 314
“The Cancer Genome Atlas (TCGA) (Brennan et al., 2013; Cancer Genome Atlas Research Network, 2008) and other genomic studies of GBM have identified several core oncogenic pathways, such as p53, Rb, and receptor tyrosine kinase (RTK)/Ras/phosphoinositide 3-kinase (PI3K) signaling (Cancer Genome Atlas Research Network, 20…”
Pollack, I. F., Agnihotri, S., & Broniscer, A. (2019) · Journal of Neurosurgery: Pediatrics · doi:10.3171/2018.10.peds18377 · Cited by 314
“37,62 One landmark observation was the detection of novel mutations in histones H3F3A (positions K27 and G34) and HIST1H3B (position K27).”
BackgroundPekmezci, M., Rice, T., Molinaro, A. M., Walsh, K. M., Decker, P. A., Hansen, H., Sicotte, H., Kollmeyer, T. M., McCoy, L. S., Sarkar, G., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1690-1 · Cited by 319
“H3 G34R (or less likely G34 V) mutations exclusive to hemispheric gliomas, which are frequently seen in teenagers and young adults, and associated with favorable prognosis may correspond to a subset of IDH-wildtype astrocytomas with ATRX mutations in this study [23].”
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 311
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
Koelsche, C., Sahm, F., Capper, D., Reuss, D., Sturm, D., Jones, D. T. W., Kool, M., Northcott, P. A., Wiestler, B., Böhmer, K., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1195-5 · Cited by 303
Self-citationHorbinski, C., Berger, T., Packer, R. J., & Wen, P. Y. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00679-w · Cited by 312
Larson, J. D., Kasper, L. H., Paugh, B. S., Jin, H., Wu, G., Kwon, C.-H., Fan, Y., Shaw, T. I., Silveira, A. B., Qu, C., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.015 · Cited by 300
“Recurrent, somatic mutation in histone H3 is a molecular hallmark distinguishing pathogenesis of HGG in children and adults (Schwartzentruber et al., 2012; Wu et al., 2014).”
BackgroundAdam, S., Polo, S. E., & Almouzni, G. (2013) · Cell · doi:10.1016/j.cell.2013.08.029 · Cited by 289
“3 recently identified in pediatric brain tumors (Schwartzentruber et al., 2012; Sturm et al., 2012; Wu et al., 2012) could misregulate the response of HIRA to DNA damage and thereby affect the maintenance of genome function.”
Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma
Jones, C., & Baker, S. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3811 · Cited by 298
Clynes, D., Jelinska, C., Xella, B., Ayyub, H., Scott, C., Mitson, M., Taylor, S., Higgs, D. R., & Gibbons, R. J. (2015) · Nature Communications · doi:10.1038/ncomms8538 · Cited by 294
“3 chromatin immunoprecipitations were performed using Millipore chromatin Immunoprecipitation Assay Kit (17-295) as per manufacturer’s instructions and 10 m g anti-histone H3.”
Fontebasso, A. M., Schwartzentruber, J., Khuong-Quang, D.-A., Liu, X.-Y., Sturm, D., Korshunov, A., Jones, D. T. W., Witt, H., Kool, M., Albrecht, S., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1095-8 · Cited by 290
“with pediatric HGG showed a highly significantly number of mutations (TP53, H3F3A, ATRX, NF1) [32] (Table S2).”
BackgroundMethodInfluentialSelf-citationStalled developmental programs at the root of pediatric brain tumors
Jessa, S., Blanchet-Cohen, A., Krug, B., Vladoiu, M., Coutelier, M., Faury, D., Poreau, B., De Jay, N., Hébert, S., Monlong, J., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0531-7 · Cited by 285
“3G34R/V) 13–19 .”
Self-citationKarremann, M., Gielen, G. H., Hoffmann, M., Wiese, M., Colditz, N., Warmuth-Metz, M., Bison, B., Claviez, A., van Vuurden, D. G., von Bueren, A. O., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox149 · Cited by 293
Self-citationMistry, M., Zhukova, N., Merico, D., Rakopoulos, P., Krishnatry, R., Shago, M., Stavropoulos, J., Alon, N., Pole, J. D., Ray, P. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3922 · Cited by 288
“Different studies reveal rates between 10% and 25%.(11,31-33) Our observations resolve some of these discrepancies, because the mutation may be specific to the subgroup of secondary pediatric HGG rather than primary pediatric HGG.”
BackgroundSelf-citationBanaszynski, L. A., Wen, D., Dewell, S., Whitcomb, S. J., Lin, M., Diaz, N., Elsässer, S. J., Chapgier, A., Goldberg, A. D., Canaani, E., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.061 · Cited by 277
“3, specifically at Lys27, have recently been discovered in pediatric glioblastomas (Schwartzentruber et al., 2012; Wu et al., 2012).”
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma
Koschmann, C., Calinescu, A.-A., Nunez, F. J., Mackay, A., Fazal-Salom, J., Thomas, D., Mendez, F., Kamran, N., Dzaman, M., Mulpuri, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac8228 · Cited by 290
“ATRX mutation in glioma is primarily seen in adolescents and young adults (ages 10 to 30 years) (1).”
BackgroundMethodInfluentialAdult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
Reuss, D. E., Kratz, A., Sahm, F., Capper, D., Schrimpf, D., Koelsche, C., Hovestadt, V., Bewerunge-Hudler, M., Jones, D. T. W., Schittenhelm, J., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1454-8 · Cited by 280
Self-citationMarked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Self-citationEpigenetic heterogeneity in cancer
Guo, M., Peng, Y., Gao, A., Du, C., & Herman, J. G. (2019) · Biomarker Research · doi:10.1186/s40364-019-0174-y · Cited by 270
Characteristics of H3 K27M-mutant gliomas in adults
Meyronet, D., Esteban-Mader, M., Bonnet, C., Joly, M.-O., Uro-Coste, E., Amiel-Benouaich, A., Forest, F., Rousselot-Denis, C., Burel-Vandenbos, F., Bourg, V., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now274 · Cited by 279
Rheinbay, E., Suvà, M. L., Gillespie, S. M., Wakimoto, H., Patel, A. P., Shahid, M., Oksuz, O., Rabkin, S. D., Martuza, R. L., Rivera, M. N., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.021 · Cited by 276
Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K., Inagaki, A., Silber, J., Gorovets, D., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H., Chan, T. A., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 278
“com/oncotarget in a phenomenon known as alternative lengthening of telomeres (ALT) along with more widespread genomic destabilization [24-26].”
InfluentialSahm, F., Reuss, D., Koelsche, C., Capper, D., Schittenhelm, J., Heim, S., Jones, D. T. W., Pfister, S. M., Herold-Mende, C., Wick, W., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1326-7 · Cited by 272
“More recent findings include mutations in the isocitrate-dehydrogenases 1 and 2 (IDH1;IDH2) as well as in the alpha-thalassemia/mental retardation syndrome X-linked gene (ATRX) in the majority of the cases [1, 16, 18, 19, 29, 35, 46].”
BackgroundSelf-citationClarke, M., Mackay, A., Ismer, B., Pickles, J. C., Tatevossian, R. G., Newman, S., Bale, T. A., Stoler, I., Izquierdo, E., Temelso, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1030 · Cited by 271
“1 ( HIST1H3B/C ) including two recurrent amino acid substitutions (K27M and G34R/V; refs.”
BackgroundSelf-citationRapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1
O'Sullivan, R. J., Arnoult, N., Lackner, D. H., Oganesian, L., Haggblom, C., Corpet, A., Almouzni, G., & Karlseder, J. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2754 · Cited by 259
“3 and the ATRX (alpha-thalassemia X-linked syndrome protein)-DAXX (death associated protein) chromatin-remodeling complex 7,8 .”
DAXX envelops a histone H3.3–H4 dimer for H3.3-specific recognition
Elsässer, S. J., Huang, H., Lewis, P. W., Chin, J. W., Allis, C. D., & Patel, D. J. (2012) · Nature · doi:10.1038/nature11608 · Cited by 251
Johnson, A., Severson, E., Gay, L., Vergilio, J.-A., Elvin, J., Suh, J., Daniel, S., Covert, M., Frampton, G. M., Hsu, S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0242 · Cited by 269
Yu, J.-R., Lee, C.-H., Oksuz, O., Stafford, J. M., & Reinberg, D. (2019) · Genes & Development · doi:10.1101/gad.325050.119 · Cited by 257
“3 variants (H3K27M) and characterizes ∼80% of DIPG (Schwartzentruber et al. 2012; Wu et al. 2012).”
BackgroundInfluentialHistone methylation and the DNA damage response
Gong, F., & Miller, K. M. (2019) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.09.003 · Cited by 248
Pathania, M., De Jay, N., Maestro, N., Harutyunyan, A. S., Nitarska, J., Pahlavan, P., Henderson, S., Mikael, L. G., Richard-Londt, A., Zhang, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.014 · Cited by 264
Self-citationMabray, M. C., Barajas, R. F., & Cha, S. (2015) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2015.3.1.8 · Cited by 237
“ATRX mutations are associated with TP53 and IDH1 mutations and are generally not seen with 1p/19q co-deletions and are thus useful in distinguishing from tumors of oligodendroglial origin [55-58].”
BackgroundZhang, H., Qin, C., An, C., Zheng, X., Wen, S., Chen, W., Liu, X., Lv, Z., Yang, P., Xu, W., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01431-6 · Cited by 247
Self-citationCastelo-Branco, P., Choufani, S., Mack, S., Gallagher, D., Zhang, C., Lipman, T., Zhukova, N., Walker, E. J., Martin, D., Merino, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70110-4 · Cited by 250
Self-citationEndogenous retroviral promoter exaptation in human cancer
Babaian, A., & Mager, D. L. (2016) · Mobile DNA · doi:10.1186/s13100-016-0080-x · Cited by 247
Developmental origins and emerging therapeutic opportunities for childhood cancer
Filbin, M., & Monje, M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0383-9 · Cited by 223
Break-Induced Replication: The Where, The Why, and The How
Kramara, J., Osia, B., & Malkova, A. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.04.002 · Cited by 238
Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases
Yao, W., Hu, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01918-w · Cited by 208
“41,42 In 2015, the NIH Roadmap Epigenomics Mapping Consortium released 111 reference human epigenomes.”
BackgroundThe effects of chromatin organization on variation in mutation rates in the genome
Makova, K. D., & Hardison, R. C. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3890 · Cited by 253
Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma
Nikbakht, H., Panditharatna, E., Mikael, L. G., Li, R., Gayden, T., Osmond, M., Ho, C.-Y., Kambhampati, M., Hwang, E. I., Faury, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11185 · Cited by 252
“However, for the purpose of this study—and more generally—we postulate three categories of mutations: (1) main driver mutations are essential to initiate and continue tumorigenesis; (2) accessory driver mutations can further promote and accelerate tumour growth but are not absolutely essential; (3) passenger mutations…”
BackgroundSelf-citationALTernative Telomere Maintenance and Cancer
Dilley, R. L., & Greenberg, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.007 · Cited by 244
Cancer epigenetics in clinical practice
Davalos, V., & Esteller, M. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21765 · Cited by 237
Popovic, R., Martinez-Garcia, E., Giannopoulou, E. G., Zhang, Q., Zhang, Q., Ezponda, T., Shah, M. Y., Zheng, Y., Will, C. M., Small, E. C., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004566 · Cited by 237
“3 was identified in pediatric glioblastoma patients, which converts lysine 27 to methionine [58].”
BackgroundFrom 1957 to Nowadays: A Brief History of Epigenetics
Peixoto, P., Cartron, P.-F., Serandour, A. A., & Hervouet, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207571 · Cited by 215
“3K36M and H3G34R/V were reported in 2012 and 2013 [155,156].”
BackgroundPaediatric and adult malignant glioma: close relatives or distant cousins?
Jones, C., Perryman, L., & Hargrave, D. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.87 · Cited by 243
Venneti, S., Garimella, M. T., Sullivan, L. M., Martinez, D., Huse, J. T., Heguy, A., Santi, M., Thompson, C. B., & Judkins, A. R. (2013) · Brain Pathology · doi:10.1111/bpa.12042 · Cited by 235
“More recently, discovery of histone H3F3A mutations at the K27 and G34 positions in pediatric glioblastomas and DIPG have brought epigenetics to the forefront of pediatric brain tumor research (14, 22, 27, 35).”
BackgroundInfluentialImpaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas
Papillon-Cavanagh, S., Lu, C., Gayden, T., Mikael, L. G., Bechet, D., Karamboulas, C., Ailles, L., Karamchandani, J., Marchione, D. M., Garcia, B. A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3757 · Cited by 243
Self-citationHistones: At the Crossroads of Peptide and Protein Chemistry
Müller, M. M., & Muir, T. W. (2015) · Chemical Reviews · doi:10.1021/cr5003529 · Cited by 247
Krug, B., De Jay, N., Harutyunyan, A. S., Deshmukh, S., Marchione, D. M., Guilhamon, P., Bertrand, K. C., Mikael, L. G., McConechy, M. K., Chen, C. C. L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.004 · Cited by 239
Self-citationHallmarks of cancer—the new testament
Senga, S. S., & Grose, R. P. (2021) · Open Biology · doi:10.1098/rsob.200358 · Cited by 221
“Replicative immortality Alternative telomere lengthening (ALT) is a telomerase-independent homologous recombination-based pathway which cancer cells use to overcome the Hayflick limit to maintain telomere length [70].”
BackgroundRakheja, D., Chen, K. S., Liu, Y., Shukla, A. A., Schmid, V., Chang, T.-C., Khokhar, S., Wickiser, J. E., Karandikar, N. J., Malter, J. S., et al. (2014) · Nature Communications · doi:10.1038/ncomms5802 · Cited by 236
“These numbers are consistent with the generally lower mutational load seen in paediatric tumours compared with tumours from adults 16,17 .”
The genomic landscape of pediatric cancers: Implications for diagnosis and treatment
Sweet-Cordero, E. A., & Biegel, J. A. (2019) · Science · doi:10.1126/science.aaw3535 · Cited by 225
Guo, R., Zheng, L., Park, J. W., Lv, R., Chen, H., Jiao, F., Xu, W., Mu, S., Wen, H., Qiu, J., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.022 · Cited by 229
“3K36 trimethylation, as likely driver mutations in a number of different tumors (Behjati et al., 2013; Lewis et al., 2013; Schwartzentruber et al., 2012; Wu et al., 2012).”
Korshunov, A., Capper, D., Reuss, D., Schrimpf, D., Ryzhova, M., Hovestadt, V., Sturm, D., Meyer, J., Jones, C., Zheludkova, O., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1493-1 · Cited by 236
“Given the almost 100 % presence of TP53 mutation and loss of ATRX in HGG_G34, in keeping with previous reports [9, 24], our findings confirm the important role of these molecular events in the pathogenesis of this neoplasm, taking into account that no other recurrent point mutations or gene fusions were found in this…”
BackgroundMethodResultSelf-citationTherapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Lin, G. L., Wilson, K. M., Ceribelli, M., Stanton, B. Z., Woo, P. J., Kreimer, S., Qin, E. Y., Zhang, X., Lennon, J., Nagaraja, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0064 · Cited by 234
Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
Paugh, B. S., Zhu, X., Qu, C., Endersby, R., Diaz, A. K., Zhang, J., Bax, D. A., Carvalho, D., Reis, R. M., Onar-Thomas, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1491 · Cited by 235
“Although the histopathologies of pediatric and adult HGGs can be similar, genome-wide studies have shown significant differences in the frequencies of specific copy number alterations (CNAs) as well as both similarities and differences in the gene expression signatures of HGGs in these two age groups (4-12).”
BackgroundResultInfluentialRecurrent MET fusion genes represent a drug target in pediatric glioblastoma
International Cancer Genome Consortium PedBrain Tumor Project (2016) · Nature Medicine · doi:10.1038/nm.4204 · Cited by 233
Self-citationTargeting EZH2 in cancer therapy
Yamagishi, M., & Uchimaru, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000390 · Cited by 225
Korshunov, A., Schrimpf, D., Ryzhova, M., Sturm, D., Chavez, L., Hovestadt, V., Sharma, T., Habel, A., Burford, A., Jones, C., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1710-1 · Cited by 227
Self-citationMackay, A., Burford, A., Molinari, V., Jones, D. T. W., Izquierdo, E., Brouwer-Visser, J., Giangaspero, F., Haberler, C., Pietsch, T., Jacques, T. S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.004 · Cited by 221
“location, clinical outcome, and a range of biological parameters (Jones and Baker, 2014; Mackay et al., 2017; Paugh et al., 2010; Schwartzentruber et al., 2012; Sturm et al., 2012;Wu et al., 2012, 2014).”
BackgroundSelf-citationAn integrative view on sex differences in brain tumors
Sun, T., Plutynski, A., Ward, S., & Rubin, J. B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1930-2 · Cited by 212
“by the frequent mutation of H3K27 to methionine in pediatric glioblastoma [32–39].”
BackgroundRamkissoon, L. A., Horowitz, P. M., Craig, J. M., Ramkissoon, S. H., Rich, B. E., Schumacher, S. E., McKenna, A., Lawrence, M. S., Bergthold, G., Brastianos, P. K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300252110 · Cited by 227
“These events have all been described in pediatric high-grade gliomas and adult gliomas with varying frequencies (15, 16).”
BackgroundSelf-citationPFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism
Jain, S. U., Do, T. J., Lund, P. J., Rashoff, A. Q., Diehl, K. L., Cieslik, M., Bajic, A., Juretic, N., Deshmukh, S., Venneti, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09981-6 · Cited by 208
Self-citationLiu, I., Jiang, L., Samuelsson, E. R., Marco Salas, S., Beck, A., Hack, O. A., Jeong, D., Shaw, M. L., Englinger, B., LaBelle, J., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01236-3 · Cited by 208
Self-citationRole of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer
Laugesen, A., Højfeldt, J. W., & Helin, K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026575 · Cited by 214
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches
Uddin, M. S., Mamun, A. A., Alghamdi, B. S., Tewari, D., Jeandet, P., Sarwar, M. S., & Ashraf, G. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.015 · Cited by 213
Gajjar, A., Bowers, D. C., Karajannis, M. A., Leary, S., Witt, H., & Gottardo, N. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.9217 · Cited by 221
Self-citationChheda, Z. S., Kohanbash, G., Okada, K., Jahan, N., Sidney, J., Pecoraro, M., Yang, X., Carrera, D. A., Downey, K. M., Shrivastav, S., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171046 · Cited by 214
“3; Schwartzentruber et al., 2012).”
The molecular landscape of glioma in patients with Neurofibromatosis 1
D’Angelo, F., Ceccarelli, M., Tala, Garofano, L., Zhang, J., Frattini, V., Caruso, F. P., Lewis, G., Alfaro, K. D., Bauchet, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0263-8 · Cited by 213
Cusanelli, E., & Chartrand, P. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00143 · Cited by 209
“Cell-cycle regulation of TERRA depends on the chromatin-remodeling protein ATRX, which loss or mutation correlate with ALT in human cancer (Heaphy et al., 2011; Lovejoy et al., 2012; Schwartzentruber et al., 2012).”
BackgroundChromatin signatures of cancer
Morgan, M. A., & Shilatifard, A. (2015) · Genes & Development · doi:10.1101/gad.255182.114 · Cited by 219
“However, immortalized Sirt6-null mouse embryonic fibroblasts (MEFs) are able to form tumors in immunocompromised mice even in the absence of transformation with an activated oncogene (Sebastian et al. 2012).”
BackgroundCatarino, R. R., & Stark, A. (2018) · Genes & Development · doi:10.1101/gad.310367.117 · Cited by 210
“More importantly, dominant PRC2 loss of function is also thought to underlie the cancer-causing effect of the H3K27Mmutant that is observed in >70%of pediatric gliomas (Schwartzentruber et al. 2012; Wu et al. 2012; Bender et al. 2013; Lewis et al. 2013; Funato et al. 2014; Herz et al. 2014).”
BackgroundNacev, B. A., Jones, K. B., Intlekofer, A. M., Yu, J. S. E., Allis, C. D., Tap, W. D., Ladanyi, M., & Nielsen, T. O. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0288-4 · Cited by 209
Pollack, I. F., Jakacki, R. I., Butterfield, L. H., Hamilton, R. L., Panigrahy, A., Potter, D. M., Connelly, A. K., Dibridge, S. A., Whiteside, T. L., & Okada, H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0526 · Cited by 208
Chromatin regulatory mechanisms and therapeutic opportunities in cancer
Valencia, A. M., & Kadoch, C. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0258-1 · Cited by 208
Histone H3.3 maintains genome integrity during mammalian development
Jang, C.-W., Shibata, Y., Starmer, J., Yee, D., & Magnuson, T. (2015) · Genes & Development · doi:10.1101/gad.264150.115 · Cited by 203
“3-encoding genes cause various types of cancer in humans, underscoring its role in maintaining tissue homeostasis (Schwartzentruber et al. 2012; Behjati et al. 2013).”
BackgroundMulti-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas
Castro-Vega, L. J., Letouzé, E., Burnichon, N., Buffet, A., Disderot, P.-H., Khalifa, E., Loriot, C., Elarouci, N., Morin, A., Menara, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7044 · Cited by 196
“Although PCC/PGL present a fairly low degree of chromosome instability, three tumours (37, 49 and 188) presented evidence of chromothripsis, consistent with the proportion of 2–3% observed in most cancers 23 .”
Alternative Lengthening of Telomeres is characterized by reduced compaction of telomeric chromatin
Episkopou, H., Draskovic, I., Van Beneden, A., Tilman, G., Mattiussi, M., Gobin, M., Arnoult, N., Londoño-Vallejo, A., & Decottignies, A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku114 · Cited by 192
Metadata
- Authors
- Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., Korbel, J. O., Hielscher, T., Hauser, P., Garami, M., Klekner, A., Bognar, L., Ebinger, M., Schuhmann, M. U., Scheurlen, W., Pekrun, A., Frühwald, M. C., Roggendorf, W., Kramm, C., Dürken, M., Atkinson, J., Lepage, P., Montpetit, A., Zakrzewska, M., Zakrzewski, K., Liberski, P. P., Dong, Z., Siegel, P., Kulozik, A. E., Zapatka, M., Guha, A., Malkin, D., Felsberg, J., Reifenberger, G., von Deimling, A., Ichimura, K., Collins, V. P., Witt, H., Milde, T., Witt, O., Zhang, C., Castelo-Branco, P., Lichter, P., Faury, D., Tabori, U., Plass, C., Majewski, J., Pfister, S. M., & Jabado, N.
- Affiliations
- McGill University and Génome Québec Innovation Centre (CA)
- German Cancer Research Center (DE)
- McGill University (CA)
- Montreal Children's Hospital (CA)
- European Molecular Biology Laboratory (DE)
- Burdenko Neurosurgery Institute (RU)
- University Children's Hospital Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Cnopf´sche Kinderklinik (DE)
- Prof. Hess Kinderklinik (DE)
- University Hospital Augsburg (DE)
- University of Würzburg (DE)
- University Hospital in Halle (DE)
- Medical University of Lodz (PL)
- University Hospital Heidelberg (DE)
- University of Toronto (CA)
- Heinrich Heine University Düsseldorf (DE)
- University of Cambridge (GB)
- McGill University Health Centre (CA)
- Corresponding author
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- ORCID
- Schwartzentruber, Jeremy
- Korshunov, Andrey
- Jones, David T. W.
- Pfaff, Elke
- Sturm, Dominik
- Hovestadt, Volker
- Albrecht, Steffen
- Kool, Marcel
- Lindroth, Anders
- Jäger, Natalie
- Rausch, Tobias
- Ryzhova, Marina
- Korbel, Jan O.
- Hielscher, Thomas
- Ebinger, Martin
- Schuhmann, Martin U.
- Frühwald, Michael C.
- Dürken, Matthias
- Atkinson, Jeffrey
- Lepage, Pierre
- Zakrzewska, Magdalena
- Liberski, Pawel P.
- Siegel, Peter
- Kulozik, Andreas E.
- Zapatka, Marc
- Guha, Abhijit
- Malkin, David
- Felsberg, Jörg
- Reifenberger, Guido
- Ichimura, Koichi
- Collins, V. Peter
- Witt, Hendrik
- Milde, Till
- Witt, Olaf
- Zhang, Cindy
- Lichter, Peter
- Faury, Damien
- Tabori, Uri
- Plass, Christoph
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- Venue
- Nature
- Published
- 2012-01-29
- Volume
- 482
- Issue
- 7384
- Pages
- 226-231
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2158233796
- Cited by
- 2,631
- References
- 35
- Citations by year
- 2026: 109 · 2025: 138 · 2024: 188 · 2023: 189 · 2022: 200 · 2021: 226 · 2020: 238 · 2019: 188 · 2018: 166 · 2017: 200 · 2016: 174 · 2015: 165 · 2014: 189 · 2013: 166 · 2012: 90
- FWCI
- 92.99
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-03-28)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- NPARC (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Funders
- Cancer Research Institute
- Genome Canada
- Brain Tumour Charity (10/106)
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- H3F3A mutation, histone H3.3, ATRX mutation, chromatin remodeling, somatic mutations, TP53 mutation, H3K27M mutation, histone modifications, histone deacetylase inhibitors
- MeSH terms
- X-linked Nuclear Protein, Base Sequence, Child, Chromatin, DNA Mutational Analysis, DNA Helicases, Glioblastoma, Histones, Humans, Molecular Sequence Data, Mutation, Nuclear Proteins, Tumor Suppressor Protein p53, Telomere, Molecular Chaperones, Gene Expression Profiling, Chromatin Assembly and Disassembly, Adaptor Proteins, Signal Transducing, Co-Repressor Proteins, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.